Paratek Pharmaceuticals paratekpharm.com


Public list: BIO 2016 (619) Smart Money VCs (6328) Pharma Startups (4732)

Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek's lead product candidate, omadacycline, is a novel tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious comm...Show all

Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek's lead product candidate, omadacycline, is a novel tetracycline-derived, broad-spectrum antibiotic being developed in both ora...Show all

Company (IPO / Went public)

Phone: 617-275-0040

Fax:

75 Kneeland Street

Boston, 02111
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Paratek Pharmaceuticals $242.9M Jul 15, 2014
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Paratek Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 22 investors

Competitors

Company Status Description Investors

Ecopia BioSciences

Quebec, Canada
MergedEcopia is finding anticancer therapies from microorganisms, one of the most prolific sources of drugs. The company's focus is to move lead compound, ECO-4601, through the different stages of its Phase I clinical trial. ECO-4601 is a small molecule with a dual mechanism of action. Not only does the compound inhibit the RAS-mitogen-activated protein kinase (MAPK) pathway at a strategic point, it also selectively binds to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in ...Show allLogin to see details

Spaltudaq

Seattle, Washington, United States
Alive / ActiveSpaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Minocycline compounds and methods of use thereof Feb 02, 2016 Aug 08, 2017 Patent
Methods of using substituted tetracycline compounds to modulate rna Jul 02, 2015 Feb 07, 2017 Patent
Substituted tetracycline compounds May 19, 2014 Jan 03, 2017 Patent
Methods for synthesizing substituted tetracycline compounds Jul 07, 2008 Dec 20, 2016 Patent
Substituted tetracycline compounds for treatment of inflammatory skin disorders Aug 19, 2013 Nov 01, 2016 Patent
See all 71 patents